3/5Autolus Therapeutics plc (AUTL): Auditor change

Market data

Price before filing: $1.49 (2026-04-15 close, split/dividend-adjusted)
Market cap at flag: $428.5M (2026-04-16) · Latest: $425.9M (2026-10-16)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: none reported.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-01-16 to 2026-05-16. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"On April 14, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of Autolus Therapeutics plc (the "Company") dismissed Ernst & Young LLP (UK) ("EY UK") as the Company's independent registered public accounting firm."

Quoted from the filing. Source

What this means

The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.

Type: dismissed
Disagreements reported: no